BACKGROUND: Choline deficiency has numerous negative health consequences; although the preponderance of the US population consumes less than the recommended Adequate Intake (AI), clinical assessment of choline status is difficult. Further, several pathways involved in primary metabolism of choline are estrogen-sensitive and the AI for premenopausal women is lower than that for men. OBJECTIVES: We sought to determine whether in vivo magnetic resonance spectroscopy (MRS) of liver and/or isotope-dilution MS of plasma could identify biomarkers reflective of choline intake (preregistered primary outcomes 1 and 2, secondary outcome 1). Determination of whether biomarker concentrations showed sex dependence was a post hoc outcome. This substudy is a component of a larger project to identify a clinically useful biomarker panel for assessment of choline status. METHODS: In a double-blind, randomized, crossover trial, people consumed 3 diets, representative of ∼100%, ∼50%, and ∼25% of the choline AI, for 2-wk periods. We measured the concentrations of choline and several metabolites using 1H single-voxel MRS of liver in vivo and using 2H-labeled isotope dilution MS of several choline metabolites in extracted plasma. RESULTS: Plasma concentrations of 2H9-choline, unlabeled betaine, and 2H9-betaine, and the isotopic enrichment ratio (IER) of betaine showed highly significant between-diet effects (q < 0.0001), with unlabeled betaine concentration decreasing 32% from highest to lowest choline intake. Phosphatidylcholine IER was marginally significant (q = 0.03). Unlabeled phosphatidylcholine plasma concentrations did not show between-diet effects (q = 0.34). 2H9 (trimethyl)-phosphatidylcholine plasma concentrations (q = 0.07) and MRS-measured total soluble choline species liver concentrations (q = 0.07) showed evidence of between-diet effects but this was not statistically significant. CONCLUSIONS: Although MRS is a more direct measure of choline status, variable spectral quality limited interpretation. MS analysis of plasma showed clear correlation of plasma betaine concentration, but not plasma phosphatidylcholine concentration, with dietary choline intake. Plasma betaine concentrations also correlate with sex status (premenopausal women, postmenopausal women, men).This trial was registered at clinicaltrials.gov as NCT03726671.
BACKGROUND: Choline deficiency has numerous negative health consequences; although the preponderance of the US population consumes less than the recommended Adequate Intake (AI), clinical assessment of choline status is difficult. Further, several pathways involved in primary metabolism of choline are estrogen-sensitive and the AI for premenopausal women is lower than that for men. OBJECTIVES: We sought to determine whether in vivo magnetic resonance spectroscopy (MRS) of liver and/or isotope-dilution MS of plasma could identify biomarkers reflective of choline intake (preregistered primary outcomes 1 and 2, secondary outcome 1). Determination of whether biomarker concentrations showed sex dependence was a post hoc outcome. This substudy is a component of a larger project to identify a clinically useful biomarker panel for assessment of choline status. METHODS: In a double-blind, randomized, crossover trial, people consumed 3 diets, representative of ∼100%, ∼50%, and ∼25% of the choline AI, for 2-wk periods. We measured the concentrations of choline and several metabolites using 1H single-voxel MRS of liver in vivo and using 2H-labeled isotope dilution MS of several choline metabolites in extracted plasma. RESULTS: Plasma concentrations of 2H9-choline, unlabeled betaine, and 2H9-betaine, and the isotopic enrichment ratio (IER) of betaine showed highly significant between-diet effects (q < 0.0001), with unlabeled betaine concentration decreasing 32% from highest to lowest choline intake. Phosphatidylcholine IER was marginally significant (q = 0.03). Unlabeled phosphatidylcholine plasma concentrations did not show between-diet effects (q = 0.34). 2H9 (trimethyl)-phosphatidylcholine plasma concentrations (q = 0.07) and MRS-measured total soluble choline species liver concentrations (q = 0.07) showed evidence of between-diet effects but this was not statistically significant. CONCLUSIONS: Although MRS is a more direct measure of choline status, variable spectral quality limited interpretation. MS analysis of plasma showed clear correlation of plasma betaine concentration, but not plasma phosphatidylcholine concentration, with dietary choline intake. Plasma betaine concentrations also correlate with sex status (premenopausal women, postmenopausal women, men).This trial was registered at clinicaltrials.gov as NCT03726671.
Authors: Kerry-Ann da Costa; Karen D Corbin; Mihai D Niculescu; Joseph A Galanko; Steven H Zeisel Journal: FASEB J Date: 2014-03-26 Impact factor: 5.191
Authors: Asma Ejaz; Laura Martinez-Guino; Allison B Goldfine; Francesc Ribas-Aulinas; Valeria De Nigris; Sílvia Ribó; Alba Gonzalez-Franquesa; Pablo M Garcia-Roves; Elizabeth Li; Jonathan M Dreyfuss; Walt Gall; Jason K Kim; Teodoro Bottiglieri; Francesc Villarroya; Robert E Gerszten; Mary-Elizabeth Patti; Carles Lerin Journal: Diabetes Date: 2016-02-08 Impact factor: 9.461
Authors: Paula Dominguez-Salas; Sophie E Moore; Maria S Baker; Andrew W Bergen; Sharon E Cox; Roger A Dyer; Anthony J Fulford; Yongtao Guan; Eleonora Laritsky; Matt J Silver; Gary E Swan; Steven H Zeisel; Sheila M Innis; Robert A Waterland; Andrew M Prentice; Branwen J Hennig Journal: Nat Commun Date: 2014-04-29 Impact factor: 14.919
Authors: Emily R Smith; Siran He; Kevin C Klatt; Matthew D Barberio; Ali Rahnavard; Negeena Azad; Carolyn Brandt; Bethany Harker; Emily Hogan; Padmini Kucherlapaty; Dina Moradian; Alison D Gernand; Homa K Ahmadzia Journal: Sci Adv Date: 2021-10-22 Impact factor: 14.136
Authors: Meriah S Schoen; Usha Ramakrishnan; Jessica A Alvarez; Thomas R Ziegler; Xiangqin Cui; Rani H Singh Journal: Nutrients Date: 2022-09-29 Impact factor: 6.706